These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 9191764)
1. A study of the effects of sumatriptan on myocardial perfusion in healthy female migraineurs using 13NH3 positron emission tomography. Lewis PJ; Barrington SF; Marsden PK; Maisey MN; Lewis LD Neurology; 1997 Jun; 48(6):1542-50. PubMed ID: 9191764 [TBL] [Abstract][Full Text] [Related]
2. Early Onset of Efficacy and Consistency of Response Across Multiple Migraine Attacks From the Randomized COMPASS Study: AVP-825 Breath Powered Silberstein S; Winner PK; McAllister PJ; Tepper SJ; Halker R; Mahmoud RA; Siffert J Headache; 2017 Jun; 57(6):862-876. PubMed ID: 28497569 [TBL] [Abstract][Full Text] [Related]
3. Introduction of a novel self-injector for sumatriptan. A controlled clinical trial in general practice. Jensen K; Tfelt-Hansen P; Hansen EW; Krøis EH; Pedersen OS Cephalalgia; 1995 Oct; 15(5):423-9. PubMed ID: 8536304 [TBL] [Abstract][Full Text] [Related]
4. Evidence against strong correlation between chest symptoms and ischemic coronary changes after subcutaneous sumatriptan injection. Tomita M; Suzuki N; Igarashi H; Endo M; Sakai F Intern Med; 2002 Aug; 41(8):622-5. PubMed ID: 12211529 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of intravenous acetylsalicylic acid lysinate compared to subcutaneous sumatriptan and parenteral placebo in the acute treatment of migraine. A double-blind, double-dummy, randomized, multicenter, parallel group study. The ASASUMAMIG Study Group. Diener HC Cephalalgia; 1999 Jul; 19(6):581-8; discussion 542. PubMed ID: 10448545 [TBL] [Abstract][Full Text] [Related]
6. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Visser WH; Jaspers NM; de Vriend RH; Ferrari MD Cephalalgia; 1996 Dec; 16(8):554-9. PubMed ID: 8980858 [TBL] [Abstract][Full Text] [Related]
8. A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults. Munjal S; Gautam A; Offman E; Brand-Schieber E; Allenby K; Fisher DM Headache; 2016 Oct; 56(9):1455-1465. PubMed ID: 27613076 [TBL] [Abstract][Full Text] [Related]
9. Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the COMPASS Study. Lipton RB; McGinley JS; Shulman KJ; Wirth RJ; Buse DC Headache; 2017 Nov; 57(10):1570-1582. PubMed ID: 28880380 [TBL] [Abstract][Full Text] [Related]
10. A randomized double-blind placebo-controlled crossover study of subcutaneous sumatriptan in general practice. Russell MB; Holm-Thomsen OE; Rishøj Nielsen M; Cleal A; Pilgrim AJ; Olesen J Cephalalgia; 1994 Aug; 14(4):291-6. PubMed ID: 7954759 [TBL] [Abstract][Full Text] [Related]
11. Managing migraine headaches experienced by patients who self-report with menstrually related migraine: a prospective, placebo-controlled study with oral sumatriptan. Dowson AJ; Massiou H; Aurora SK J Headache Pain; 2005 Apr; 6(2):81-7. PubMed ID: 16362647 [TBL] [Abstract][Full Text] [Related]
12. Acute treatment of migraine attacks: efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-potassium, in comparison to oral sumatriptan and placebo. The Diclofenac-K/Sumatriptan Migraine Study Group. Cephalalgia; 1999 May; 19(4):232-40. PubMed ID: 10376168 [TBL] [Abstract][Full Text] [Related]
13. Sumatriptan Iontophoretic Transdermal System Reduces Treatment-Emergent Nausea and Is Effective in Patients With and Without Nausea at Baseline - Results From a Randomized Controlled Trial. Bigal ME; Lipton RB; Newman LC; Pierce MW; Silberstein SD Headache; 2015 Sep; 55(8):1124-32. PubMed ID: 26178815 [TBL] [Abstract][Full Text] [Related]
14. An open-label trial of a sumatriptan auto-injector for migraine in patients currently treated with subcutaneous sumatriptan. Landy SH; Tepper SJ; Wein T; Schweizer E; Ramos E Headache; 2013 Jan; 53(1):118-125. PubMed ID: 23148799 [TBL] [Abstract][Full Text] [Related]
15. The efficacy and safety of sc alniditan vs. sc sumatriptan in the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. Diener HC; Tfelt-Hansen P; de Beukelaar F; Ferrari MD; Olesen J; Dahlöf C; Mathew N; Cephalalgia; 2001 Jul; 21(6):672-9. PubMed ID: 11531899 [TBL] [Abstract][Full Text] [Related]
16. Safety, tolerability, and pharmacokinetics of sumatriptan in healthy subjects following ascending single intranasal doses and multiple intranasal doses. Moore KH; Hussey EK; Shaw S; Fuseau E; Duquesnoy C; Pakes GE Cephalalgia; 1997 Jun; 17(4):541-50. PubMed ID: 9209776 [TBL] [Abstract][Full Text] [Related]
17. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463 [TBL] [Abstract][Full Text] [Related]
18. [Use of triptanes according to indications. Risk of infarct is not increased]. MMW Fortschr Med; 2004 Feb; 146(7):60. PubMed ID: 15347059 [No Abstract] [Full Text] [Related]
19. Oral sumatriptan for migraine in children and adolescents: a randomized, multicenter, placebo-controlled, parallel group study. Fujita M; Sato K; Nishioka H; Sakai F Cephalalgia; 2014 Apr; 34(5):365-75. PubMed ID: 24163282 [TBL] [Abstract][Full Text] [Related]
20. Sumatriptan. A reappraisal of its pharmacology and therapeutic efficacy in the acute treatment of migraine and cluster headache. Plosker GL; McTavish D Drugs; 1994 Apr; 47(4):622-51. PubMed ID: 7516861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]